Extended ( ≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials
To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab ≥q12 or (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Authors: Rahul N. Khurana, Ehsan Rahimy, W. Anthony Joseph, Namrata Saroj, Andrea Gibson, Robert Vitti, Alyson J. Berliner, Karen Chu, YenChieh Cheng, David S. Boyer Tags: Original Articles Source Type: research

Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials
To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab every 12  weeks or longer (≥q12 weeks) or less than every 12 weeks ( (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Authors: Rahul N. Khurana, Ehsan Rahimy, W. Anthony Joseph, Namrata Saroj, Andrea Gibson, Robert Vitti, Alyson J. Berliner, Karen Chu, YenChieh Cheng, David S. Boyer Tags: Original article Source Type: research

One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema
Conclusion: Our results suggest that not all patients with DME require a fixed loading phase when initiating anti-VEGF treatment. Finding anatomical predictors to identify this subgroup of patients would help to reduce treatment burden and optimize clinical outcomes.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - January 17, 2019 Category: Opthalmology Source Type: research

Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
To report the first case of human herpesvirus-6 (HHV-6) corneal endotheliitis that developed after intravitreal ranibizumab injections. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - January 16, 2019 Category: Opthalmology Authors: Masahiro Onda, Yusuke Niimi, Kenji Ozawa, Ikumi Shiraki, Kiyofumi Mochizuki, Tetsuya Yamamoto, Sunao Sugita and Kyoko Ishida Tags: Case report Source Type: research

Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells
Conclusion: Combination of ranibizumab and amfenac reduced the proliferation rate of uveal melanoma cells; however, only amfenac monotherapy significantly decreased cell migration. The radiosensitivity of the 92.1 uveal melanoma cell line increased following the administration of ranibizumab, amfenac, and their combination. Further investigation is warranted to determine if this is a viable pretreatment strategy to render large tumors amenable to radiotherapy.RESUMO Objetivo: Avaliar os efeitos do ranibizumabe em associa ção com o amfenac nas células de melanoma uveal humano e explorar a capacidade des...
Source: Arquivos Brasileiros de Oftalmologia - January 15, 2019 Category: Opthalmology Source Type: research

Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpos... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - January 15, 2019 Category: Opthalmology Authors: Zhongjing Lin, Qiwei Hu, Yanlin Wu, Jianmin Xu and Qiong Zhang Tags: Case report Source Type: research

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
To identify baseline patient characteristics associated with early clinically significant visual acuity (VA) improvements within 3  months of treatment initiation in ranibizumab-treated patients with retinal ve... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - January 8, 2019 Category: Opthalmology Authors: W. Lloyd Clark, Mimi Liu, John Kitchens, Pin-wen Wang and Zdenka Haskova Tags: Research article Source Type: research

A Traditional Chinese Patent Medicine ZQMT for Neovascular Age-Related Macular Degeneration: a multicenter randomized clinical trial.
Abstract BACKGROUND: Anti-VEGF agent ranibizumab has been extensively used as a standard treatment for wet AMD. We investigated whether traditional Chinese medicine could serve as a complimentary therapy for this disease. METHODS: 144 patients with neovascular age-related macular degeneration received either intravitreal ranibizumab treatment as needed plus placebo or intravitreal ranibizumab treatment as needed plus a Chinese FDA approved traditional Chinese patent medicine named ZQMT. Both groups received treatment for 24 weeks. The primary outcome was the mean change of visual acuity at week 24 as compared...
Source: Current Molecular Medicine - January 7, 2019 Category: Molecular Biology Authors: Jin M, Dai H, Zhang X, Wang Y, Han M, Zhang H, Liu Y, Wang Z, Gao X, Li L, Wen X, Liu Y, Wei L, Chen Y Tags: Curr Mol Med Source Type: research

Impact of angiogenic activation and inhibition on miRNA profiles of human retinal endothelial cells.
CONCLUSION: In this study we characterized the miRNA profile of HRMVECs under resting, angiogenic and anti-angiogenic conditions and identified several miRNAs of potential pathophysiologic importance for angioproliferative retinal diseases. Our results have implications for possible miRNA-targeted angiomodulatory approaches in diseases like diabetic retinopathy or retinopathy of prematurity. PMID: 30615884 [PubMed - as supplied by publisher] (Source: Experimental Eye Research)
Source: Experimental Eye Research - January 4, 2019 Category: Opthalmology Authors: Walz JM, Wecker T, Zhang PP, Cakir B, Gruening B, Agostini H, Reuer T, Ludwig F, Boneva S, Faerber L, Lange C, Schlunck GR, Stahl A Tags: Exp Eye Res Source Type: research

Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
CONCLUSION: Larger CNV and the presence of a peaked PED appeared to be associated with a good early response, and the drug type seemed to be associated with both early and late poor anatomical response of anti-VEGF treatment in nAMD patients. Aflibercept appears to be more effective than ranibizumab in regards to the percentage of patients with better anatomical response in both the early and late treatment periods. PMID: 30578008 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - December 24, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment
Conclusion: Optical coherence tomography leakage changes after anti–vascular endothelial growth factor treatment of diabetic macular edema, identifying the degree of decrease in retinal fluid in the outer layers of the retina is a more robust biomarker of BCVA recovery than central retinal thickness, disorganization of the inner retinal layer, or ellipsoid zone disruption changes. (Source: RETINA)
Source: RETINA - December 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial
Purpose: Compare changes in retinal nerve fiber layer (RNFL) thickness between eyes assigned to intravitreous ranibizumab or panretinal photocoagulation and assess correlations between changes in RNFL and visual field sensitivity and central subfield thickness. Methods: Eyes with proliferative diabetic retinopathy were randomly assigned to ranibizumab or panretinal photocoagulation. Baseline and annual follow-up spectral domain optical coherence tomography RNFL imaging, optical coherence tomography macular imaging, and automated static perimetry (Humphrey visual field 60–4 algorithm) were performed. Results: ...
Source: RETINA - December 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data
Purpose: This post hoc analysis explores the relationship between early retinal anatomical response and long-term anatomical and visual outcomes with ranibizumab in center-involved diabetic macular edema. Methods: Eyes randomized to the ranibizumab plus prompt laser and ranibizumab plus deferred laser treatment arms in the Protocol I study were categorized according to their proportional reduction ( (Source: RETINA)
Source: RETINA - December 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

A 5-Year-Old Case of Choroidal Neovascularization in Enhanced S-Cone Syndrome Treated with Ranibizumab
Conclusion: CNV has been reported to occur in different inherited retinal degenerations, including ESCS. Our experience confirms that treatment with ranibizumab in patients with CNV-complicated ESCS can be potentially vision-saving.Case Rep Ophthalmol 2018;9:510 –515 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - December 21, 2018 Category: Opthalmology Source Type: research

Incidence of exudative age-related macular degeneration and treatment load under the Korean national health insurance system in 2010-2015.
CONCLUSIONS: This study describes the incidence of exudative AMD in South Korea and its treatment under the national health insurance system in this country. Its findings could be used for reference purposes and be useful when planning treatment for exudative AMD. PMID: 30573498 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 20, 2018 Category: Opthalmology Authors: Rim TH, Yoo TK, Kim SH, Kim DW, Kim SS Tags: Br J Ophthalmol Source Type: research

Combined central retinal artery and vein occlusion; first manifestation of lupus in a pediatric patient.
Authors: Moreno Páramo D, Rayón Rodríguez MA, García Leonardo JI Abstract Combined central retinal artery and vein occlusion is uncommon in adults and even more so in young people. The main origins are vasculitis and thromboembolic disorders. The prognosis is poor due to irreversible visual loss and the development of neovascular glaucoma (NVG). A 14 year-old male arrived at the clinic complaining of sudden and painless visual loss in the left eye. Best corrected visual acuity was light perception with clinical and fluoro-angiographic findings characteristic of combined central retinal a...
Source: Archivos de la Sociedad Espanola de Oftalmologia - December 19, 2018 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
CONCLUSION: Increased utilization of anti-VEGF agents can reduce SVI and legal blindness in patients with DME in Japan. This would also be associated with substantial savings in patient and caregiver productivity loss. PMID: 30550375 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 16, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Authors: Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M Abstract PURPOSE: To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-vascular endothelial growth factor (VEGF) treatment of retinopathy of prematurity (ROP). METHODS: We performed a retrospective review of intravitreal anti-VEGF (bevacizumab or ranibizumab) treatment of 153 eyes (83 infants) diagnosed with ROP at two tertiary hospitals from June 2011 to January 2017. The primary outcome was the rate of recurrence requiring additional treatment; secondary outcomes included incidence of major complicatio...
Source: Korean Journal of Ophthalmology : KJO - December 16, 2018 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes.
CONCLUSIONS There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL. PMID: 30542050 [PubMed - in process] (Source: Medical Science Monitor)
Source: Medical Science Monitor - December 15, 2018 Category: Research Tags: Med Sci Monit Source Type: research

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD.
Conclusion: The anti-VEGF therapy was frequently required in nAMD patients with a history of heavy smoking. Heavy smoking could cause poor therapeutic response in nAMD patients. PMID: 30538852 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - December 14, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab
To compare the rates of infectious endophthalmitis following intravitreal injection of ranibizumab using prefilled syringes vs. conventional preparation. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 13, 2018 Category: Opthalmology Authors: Philip P. Storey, Zujaja Tauqeer, Yoshihiro Yonekawa, Bozho Todorich, Jeremy D. Wolfe, Sumit P. Shah, Ankoor R. Shah, Takashi Koto, Ashkan M. Abbey, Yuki Morizane, Priya Sharma, Edward H. Wood, Mio Morizane-Hosokawa, Pooja Pendri, Maitri Pancholy, Shawn H Tags: Original Articles Source Type: research

Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
Abstract PURPOSE:: To compare the outcome of the sequence in the two treatments (intravitreal ranibizumab and panretinal photocoagulation) in high-risk proliferative diabetic retinopathy. METHODS:: This retrospective study included 35 patients with newly diagnosed high-risk proliferative diabetic retinopathy in 43 eyes; 18 (22 eyes) received intravitreal ranibizumab before panretinal photocoagulation (intravitreal ranibizumab+ group), while the other 17 (21 eyes) received panretinal photocoagulation before intravitreal ranibizumab (panretinal photocoagulation+ group). Each subject received three intravitreal ...
Source: European Journal of Ophthalmology - December 12, 2018 Category: Opthalmology Authors: Cao G, Xu X, Wang C, Zhang S Tags: Eur J Ophthalmol Source Type: research

Effects of ranibizumab (Lucentis ®) and bevacizumab (Avastin®) on human corneal endothelial cells
Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are ... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - December 11, 2018 Category: Opthalmology Authors: Patrick R. Merz, Nina R öckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack Tags: Research article Source Type: research

Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration
Intravitreal ranibizumab injection (IRI) is effective for patients with exudative age-related macular degeneration (AMD) and decreases intraocular levels of vascular endothelial growth factor (VEGF), but VEGF ... (Source: Journal of Inflammation)
Source: Journal of Inflammation - December 4, 2018 Category: Allergy & Immunology Authors: Ryosuke Motohashi, Hidetaka Noma, Kanako Yasuda, Osamu Kotake, Hiroshi Goto and Masahiko Shimura Tags: Research Source Type: research

Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety.
CONCLUSION: Intravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging. PMID: 30514709 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 4, 2018 Category: Opthalmology Authors: Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M Tags: Br J Ophthalmol Source Type: research

Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
Abstract AIM: To determine whether there are factors that can predict the frequency of recurrences of macular oedema associated with branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 31 eyes with treatment-naïve macular oedema associated with BRVO. All eyes received an intravitreal ranibizumab (IVR) injection and were followed with a pro re nata protocol for at least 12 months. A reinjection of ranibizmab was performed when the central foveal thickness was ≥300 µm. At 1 month after IVR injection, the macular vessel reduction was calculated by comparing the ...
Source: The British Journal of Ophthalmology - December 4, 2018 Category: Opthalmology Authors: Hasegawa T, Takahashi Y, Maruko I, Kogure A, Iida T Tags: Br J Ophthalmol Source Type: research

Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes
SIGNIFICANCE We compared the 24-month outcomes of ranibizumab and dexamethasone implants in treatment-naive branch retinal vein occlusion patients. Ranibizumab was effective in improving visual outcomes, whereas the dexamethasone implant was not. PURPOSE The aim of this study was to compare the 2-year real-world outcomes of intravitreal ranibizumab with dexamethasone implants in patients with macular edema secondary to branch retinal vein occlusion. METHODS The treatment-naive branch retinal vein occlusion patients with macular edema who were treated with intravitreal ranibizumab or dexamethasone implant were inclu...
Source: Optometry and Vision Science - December 1, 2018 Category: Opthalmology Tags: ORIGINAL INVESTIGATIONS Source Type: research

Subthreshold micropulse laser photocoagulation therapy in a case of bilateral retinal astrocytic hamartomas with tuberous sclerosis complex: A case report
Rationale: Report a case of bilateral multiple retinal hamartomas (RAHs) in a patient with tuberous sclerosis complex (TSC) and introduced a new method (subthreshold micropulse laser photocoagulation) for the treatment of RAHs. Patient concerns: A 20-year-old man with TSC complained of decreased vision and metamorphosia in both eyes for 2 months. At presentation, visual acuity (VA) was 20/32 in the right eye and 20/40 in the left eye. Fundus photographs, optical coherence tomography, fundus fluorescein angiography (FFA), and indocyanine green angiography indicated multiple RAHs in both eyes. Diagnoses: Bilateral re...
Source: Medicine - December 1, 2018 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab for CRVO
This randomized clinical trial determines the 2-year efficacy of laser-induced chorioretinal anastomosis procedure plus intravitreal ranibizumab therapy vs sham procedure plus intravitreal ranibizumab therapy for patients with macular edema caused by central retinal vein occlusion. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - December 1, 2018 Category: Opthalmology Source Type: research

[Evaluation of intravitreal injection practice patterns in Cotonou].
CONCLUSION: Intravitreal injection is a common practice in our context, which is being performed safely. The indications are many, and ocular hypertension is a significant complication. The difficulties in terms of supply and preservation of the main drugs used (anti-VEGF) remains to be resolved. PMID: 30470487 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - November 26, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

The Developing Regorafenib Eye drops for neovascular Age ‐related Macular degeneration (DREAM) study: an open‐label phase II trial
ConclusionsThe programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaboratepost hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye). (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 25, 2018 Category: Drugs & Pharmacology Authors: Antonia M. Joussen, Sebastian Wolf, Peter K. Kaiser, David Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Gesa Deeg, Annett Richter, Torsten Zimmermann, Joachim Hoechel, Ulf Buetehorn, Walter Schmitt, Brigitte Stemper, Michael K. B Tags: ORIGINAL ARTICLE Source Type: research

Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results
ConclusionsAt 12 months after beginning treatment, the reduction in the SRD thickness affects macular function recovery. As recurrences of the PED can occur during the PRN period, control of the PED is necessary to obtain good macular function for the long term. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - November 23, 2018 Category: Opthalmology Source Type: research

Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema
This study evaluates the effectiveness of a single-dose dexamethasone implant (DI) as an auxiliary therapy to continued intravitreal ranibizumab (IVR) treatment in patients with persistent diabetic macular edema (DME).MethodsTwenty-five pseudophakic eyes of 25 patients with DME who underwent a single injection of DI as an adjuvant therapy following an IVR loading dose were examined retrospectively. All patients were treatment naive and had a poor response to a loading dose of three consecutive monthly IVR injections. IVR treatments were continued pro re nata after the DI. The main outcome measures were changes in best-corr...
Source: International Ophthalmology - November 23, 2018 Category: Opthalmology Source Type: research

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
Purpose: To analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab. Methods: Multicenter, prospective, nonrandomized clinical trial. One eye of patients presenting neovascular age–related macular degeneration with PED of more than 250 μm in height, with persistent fluid, was included. Patients had to have received at least six ranibizumab intravitreal injections during the 12 months before enrollment. Patients were switched from ranibizumab pro re nata to aflibercept (fixed regimen, 3 monthly intravitreal injec...
Source: RETINA - November 17, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Efficacy of ultra-low-dose (0.1  mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series.
CONCLUSION:: Intravitreal injection of ultra-low-dose ranibizumab showed promising efficacy and good ocular safety. However, further large-scale studies are required to give stronger evidence about the efficacy and safety of ultra-low-dose ranibizumab. PMID: 30428702 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - November 15, 2018 Category: Opthalmology Authors: Ahmed IS, Hadi AM, Hassan HH Tags: Eur J Ophthalmol Source Type: research

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
We aimed to analyze the differences in the prevalence of outer retinal tubulation (ORT) in neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) ag... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - November 14, 2018 Category: Opthalmology Authors: Attila Kovacs, Timea Kiss, Ferenc Rarosi, Gabor M. Somfai, Andrea Facsko and Rozsa Degi Tags: Research article Source Type: research

Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Abstract Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomis...
Source: The British Journal of Ophthalmology - November 8, 2018 Category: Opthalmology Authors: Low A, Faridi A, Bhavsar KV, Cockerham GC, Freeman M, Fu R, Paynter R, Kondo K, Kansagara D Tags: Br J Ophthalmol Source Type: research

Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports
Polypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine g... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - November 3, 2018 Category: Opthalmology Authors: Yasuhiro Iesato, Masaaki Tanaka, Masako Murata, Junya Kitahara, Takao Hirano, Taihei Kurenuma, Noriko Yoshida and Toshinori Murata Tags: Case report Source Type: research

Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch
ConclusionThe effect achieved from a single dose in patients switched to aflibercept or ranibizumab reduced significantly CMT measurements. Comparing aflibercept and ranibizumab, the effect appears to be similar in both drugs, in terms of reduction of CMT. (Source: International Ophthalmology)
Source: International Ophthalmology - November 1, 2018 Category: Opthalmology Source Type: research

Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema.
CONCLUSIONS: The inclusion of an intravitreal dexamethasone implant for the  treatment of diabetic macular oedema would lead to cost-savings for the  considered health area, mainly by reducing the administration costs. PMID: 30381045 [PubMed - in process] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - November 1, 2018 Category: Drugs & Pharmacology Authors: Cervera E, De Andrés-Nogales F, Armadá F, Arias L, Oyagüez I, Martínez C Tags: Farm Hosp Source Type: research

Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab.
Authors: Chiumente M, Damuzzo V, Agnoletto L, Leonardi L, Mengato D Abstract PMID: 30369396 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - October 31, 2018 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation
AbstractTopical delivery of therapeutics to the posterior segment of the eye remains the “holy grail” of ocular drug delivery. As an example, anti–vascular endothelial growth factor biologics, such as ranibizumab, aflibercept, and bevacizumab, are delivered by intravitreal injection to treat neovascular age-related macular degeneration and, although these drugs have revolutionized treatment of the disease, less invasive alternatives to intravitreal injection are desired. Multiple reports in the literature have demonstrated topical delivery of both small and large molecules to the back of the eye in small ...
Source: Pharmaceutical Research - October 29, 2018 Category: Drugs & Pharmacology Source Type: research

Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers.
Authors: Weingessel B, Miháltz K, Gleiss A, Sulzbacher F, Schütze C, Vécsei-Marlovits PV Abstract Purpose: Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal antivascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics. Methods: Prospective clinical trial (50 treatment-naive eyes) with DME randomized 1 : 1 receiving intravitreal ranibizumab (0.5 mg/0.05 ml) and prompt grid laser compared with ranibizumab and deferred laser. Morphological characteristic...
Source: Journal of Ophthalmology - October 28, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
CONCLUSION: Intravitreal aflibercept is evaluated to be presenting significant visual and anatomical improvements in patients with persistent macular edema due to CRVO despite previous intravitreal ranibizumab. PMID: 30361176 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - October 27, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Facile synthetic Photoluminescent Graphene Quantum dots encapsulated β-cyclodextrin drug carrier system for the management of macular degeneration: Detailed analytical and biological investigations
Publication date: Available online 26 October 2018Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Cheng Qian, Panshi Yan, Guangming Wan, Shenzhi Liang, Yi Dong, Jiong WangAbstractDrug administration by effective nano-carriers is an emerging and growing technology in the field of bio-medicine and particularly Age –related macular degeneration (AMD). This developed nanomaterials based methods with drug administration maximizes the biocompatibility and systemically increases drug delivery profile for the drugs. Herein, we described the effective drug molecules delivery profiles by the hydrotherma...
Source: Journal of Photochemistry and Photobiology B: Biology - October 26, 2018 Category: Speech-Language Pathology Source Type: research

[Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)].
This article analyzes the agreement between the diagnosis documented by the treating ophthalmologist and the evaluation of reading centers at baseline as well as the effect on the response to treatment during the course. METHODS: A total of 396 patients (age 75.4 years) were enrolled in which ranibizumab treatment was indicated by the treating ophthalmologist due to either diabetic macular edema (DME), neovascular age-related macular degeneration (nvAMD) or retinal venous occlusion (RVO). Over a period of 24 months, patient and examination data, treatments and interpretation of retinal imaging data...
Source: Der Ophthalmologe - October 26, 2018 Category: Opthalmology Authors: Brinkmann CK, Chang P, Schick T, Heimes B, Vögeler J, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S Tags: Ophthalmologe Source Type: research

Clinical preferences and trends of anti ‐vascular endothelial growth factor treatments for diabetic macular edema in Japan
ConclusionsOur results present the current clinical preferences of anti ‐VEGF treatment for DME in Japan. The best‐corrected visual acuity and the retinal thickness are important indicators to institute this therapy. The majority of the ophthalmologists use anti‐VEGF treatment as first‐line therapy and prefer the 1 + pro re nata regimen. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - October 26, 2018 Category: Endocrinology Authors: Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Tags: Original Article Source Type: research

Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization
Conclusion: There was no difference between the aflibercept and ranibizumab treatments in terms of visual acuity improvement after 12 months in patients with Type 3 neovascularization. However, geographic atrophy developed more frequently in the aflibercept-treated group. (Source: RETINA)
Source: RETINA - October 25, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-asian patients from the radiance study
Purpose: To evaluate long-term efficacy and safety of ranibizumab for treatment of myopic choroidal neovascularization (mCNV) in clinical practice. Methods: Noninterventional, retrospective cohort study of East-Asian patients previously treated with ranibizumab during the RADIANCE trial. Forty-one patients who completed the RADIANCE trial were followed-up for up to 48 months (post-RADIANCE observation period). Outcome measures were best-corrected visual acuity changes from baseline (assessed at RADIANCE trial initiation), mCNV recurrences, and ocular adverse events. Results: Mean visual gain from baseline best-corr...
Source: RETINA - October 25, 2018 Category: Opthalmology Tags: Original Study Source Type: research